Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Delmer

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|August 20, 2008
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemiaBruno Cazin, Marine Divine, Stéphane Leprêtre, et al.
Molecular Cancer|May 22, 2010
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemiaEtienne Moussay, Valérie Palissot, Laurent Vallar, et al.
American Journal of Hematology|January 23, 2016
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort studyEmmanuel Bachy, Jane A Estell, Eric Van de Neste, et al.
Blood|August 14, 2012
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphismsHervé Ghesquières, Guillaume Cartron, John Francis Seymour, et al.
British Journal of Haematology|April 21, 2022
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)Guillaume Manson, Charles Herbaux, Jean-Marc Schiano, et al.
Blood|June 28, 2019
Prevalence of <i>BTK</i> and <i>PLCG2</i> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
Blood|September 30, 2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populationsJohn R Mackey, Carlos M Galmarini, Kathryn A Graham, et al.
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
The Lancet. Oncology|April 13, 2013
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trialRichard Delarue, Hervé Tilly, Nicolas Mounier, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|August 20, 2008
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemiaBruno Cazin, Marine Divine, Stéphane Leprêtre, et al.
Molecular Cancer|May 22, 2010
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemiaEtienne Moussay, Valérie Palissot, Laurent Vallar, et al.
American Journal of Hematology|January 23, 2016
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort studyEmmanuel Bachy, Jane A Estell, Eric Van de Neste, et al.
Blood|August 14, 2012
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphismsHervé Ghesquières, Guillaume Cartron, John Francis Seymour, et al.
British Journal of Haematology|April 21, 2022
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)Guillaume Manson, Charles Herbaux, Jean-Marc Schiano, et al.
Blood|June 28, 2019
Prevalence of <i>BTK</i> and <i>PLCG2</i> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
Blood|September 30, 2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populationsJohn R Mackey, Carlos M Galmarini, Kathryn A Graham, et al.
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
The Lancet. Oncology|April 13, 2013
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trialRichard Delarue, Hervé Tilly, Nicolas Mounier, et al.
Pageof 11